Director, Banner Alzheimer's Institute; Research Professor of Psychiatry, University of Arizona
Psychiatry
Dr. Pierre N. Tariot, MD
|
|
Give Review
Pierre N. Tariot is an expert in the field of Psychiatry. He researched medicine at University of Rochester School of Medicine and Dentistry. He received awards:"Top Doctors:Arizona State" and "Super Doctor". Pierre Tariot is also published. He has 51 publications published. The lastest publication: "Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.' He is registered with Medicare and accepts Medicare payments.
Publications
- Diagnostic accuracy of CERAD total score in a Colombian cohort with mild cognitive impairment and Alzheimer's disease affected by E280A mutation on presenilin-1 gene.
- Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: A Cross-sectional Study.
- Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation.
- Arizona Alzheimer's Registry: Strategy and Outcomes of a Statewide Research Recruitment Registry.
- When should neuroprotective drugs move from mice to men?
- Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis.
- Endpoints in preclinical alzheimer's disease trials.
- The alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical alzheimer's disease treatments in preseni...
- Ushering in the study and treatment of preclinical Alzheimer disease.
- Alzheimer's disease: the importance of early diagnosis and appropriate management.
- Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control...
- Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or...
- Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD.
- Why does mommy forget?
- When is it dementia?
- Mild cognitive impairment: diagnosis and treatment dilemmas.
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double...
- MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population.
- Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial ...
- Can lithium or valproate untie tangles in Alzheimer's disease?
- Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
- Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." A national registry to identify a cohort for Alzheimer's disease preve...
- Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.
- Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.
- Psychosis and agitation in dementia: should general psychiatrists care?
- Clinical trials of amyloid-based therapies for Alzheimer's disease.
- Meta-analysis of six-month memantine trials in Alzheimer's disease.
- Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
- Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
- What do people at risk for Alzheimer disease think about surrogate consent for research?
- Pharmacological treatment of neuropsychiatric symptoms of dementia.
- Purchasing or providing nursing home care: can quality of care data provide guidance.
- Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease.
- Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
- Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
- Efficacy of atypical antipsychotics in elderly patients with dementia.
- Clinical effectiveness of atypical antipsychotics in dementia.
- Current treatment for Alzheimer disease and future prospects.
- Alzheimer disease: current challenges, emerging treatments.
- Managing psychosis in long-term care: treating the whole patient.
- Valproate therapy for agitation in dementia: open-label extension of a double-blind trial.
- Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
- Medical management of advanced dementia.
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
- Valproate use in neuropsychiatric Disorders in the elderly.
- Neuroprotective properties of valproate: potential benefit for AD and tauopathies.
- Psychopharmacologic interventions in nursing homes: what do we know and where should we go?
- Pharmacotherapy for the older patient with psychosis.
- Provisional diagnostic criteria for depression of Alzheimer disease.
- Use of quetiapine in elderly patients.
Schools
University Of Rochester
Procedures Preformed
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Adjustment Disorder
- Major Depressive Disorder
Doctors Specialties
- Geriatric Psychiatry
- Psychiatry
Accepted Insurances
Awards
- Top Doctors:Arizona State
- Super Doctor
Education
-
National Institutes of Health Clinical Center -
University of Wisconsin -
University of Rochester School of Medicine and Dentistry
Hospital
-
Banner Good Samaritan Medical Center
Drug Facts
| NPI NUMBER | 1568429025 | |
| NPPES Provider LastName | TARIOT | |
| NPPES Provider FirstName | PIERRE | |
| NPPES Provider ZIPCode | 850062727 | |
| NPPES Provider State | AZ | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 423.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568429025 |
| Last Name Of The Provider | TARIOT |
| First Name Of The Provider | PIERRE |
| View All |
Similar Doctors
|
|
Dr. Anna D. Burke, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eva B. McCullars, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary J. Maymana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee A. Kelley, MD |
|
|
Dr. Todd A. Rowe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naeem A. Pathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew Goldenberg, DO |
|
Dr. Curtis A. McKnight, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yukari K. Wey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arash Zamanian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sasha G. Hamdani, MD |
|
|
Nicole L. Faulkinbury, LPN |
|
|
Dr. Ilhan Conklu, MD |